Bio Developments

Applications of nanotech may provide bioavailability

26-Mar-2019 By Maggie Lynch

Nanotechnology may be able to increase bioavailability in low-solubility drugs and improve a drug’s chance of success, according to Ascendia CEO.

A troubled timeline of Alzheimer’s trials

22-Mar-2019 By Ben Hargreaves

After Biogen’s setback in the space, the number of treatments that have not succeeded in making an impact on Alzheimer’s disease continues to grow.

Pfizer secures option to acquire Vivet for up to $635.8m

20-Mar-2019 By Maggie Lynch

Pfizer secures an exclusive option to acquire Vivet for up to $635.8m after collaborating with the biotech to develop an AAV gene therapy treatment.

Abzena tapped as CMC for Lipum’s biologic development project

20-Mar-2019 By Maggie Lynch

Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the former’s proprietary cell line and GMP resources.

Vertex receives approval and develops triple combination gene therapy for CF

19-Mar-2019 By Maggie Lynch

Vertex’s Symdeko approved in Australia, after FDA approval in 2018, as the company works to develop triple combination gene therapies for CF.

Technology boosts access to biologics and insulin via oral delivery

18-Mar-2019 By Maggie Lynch

Drug delivery of biologics takes a sharp turn, as the development of pills that can replace injections and increase drug accessibility moves forward.

First oncology mAb biosimilar from Pfizer approved by FDA

14-Mar-2019 By Maggie Lynch

US FDA approves Pfizer’s Trazimera, a biosimilar to Roche’s blockbuster product, Herceptin, for the treatment of HER2 positive breast cancer.

$4bn collaboration sees Abpro expand its global capabilities

07-Mar-2019 By Maggie Lynch

Abpro and NJCTTQ enter $4bn agreement to develop bispecific antibody therapies for immuno-oncology and extend its global reach.

Lilly cuts insulin price 50% after congressional hearing

06-Mar-2019 By Ben Hargreaves

Lilly announces the launch of a generic version of Humalog, which will be available in the US with a list price 50% lower than the brand product.

Cell therapy market to triple in size by 2025

04-Mar-2019 By Ben Hargreaves

The market for cell therapy products is set to expand based on increasing investment from the industry and the implementation of advanced manufacturing technologies.

Global cell line development market to reach $7.5bn by 2024

01-Mar-2019 By Maggie Lynch

The global cell line development market grows steadily with a predicted revenue of $7.5bn by 2024, each component of the market to see CAGR between 10-15%.

Blackstone launches cardio-focused biopharma with Novartis

28-Feb-2019 By Maggie Lynch

Blackstone launches Anthos Therapeutics, with the help of Novartis, to develop targeted therapies for cardiovascular disease.

ABL extends antibody agreement in $220m deal with WuXi Biologics

27-Feb-2019 By Maggie Lynch

ABL will use WuXi’s platforms in an extended agreement for the development and commercialization of its bispecific antibodies, using the recently launched WuXiBody platform.

AbbVie and Voyager develop gene therapies for Parkinson's

27-Feb-2019 By Maggie Lynch

AbbVie expands partnership with Voyager for the R&D of vectorized antibodies for the treatment of Parkinson’s disease gene therapies.

Novartis doubles investment in AveXis North Carolina site

20-Feb-2019 By Ben Hargreaves

In addition to the $55m previously invested, Novartis will spend a further $60m in expanding AveXis’ site in North Carolina enabling the manufacture of multiple gene therapies simultaneously.